Skip to content

Prospective study of pathology and radiology data collection in retroperitoneal sarcoma patients

REtroperitoneal SArcoma Registry (RESAR): prospective collection of primary retroperitoneal sarcoma patientâ??s data, radiological and pathological material for the TransAtlantic Australasian Retroperitoneal Sarcoma Working Group - Resar

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/10/037541
Enrollment
75
Registered
2021-10-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C480- Malignant neoplasm of retroperitoneum

Interventions

None listed

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -primary RPS operated on in the participating center -primary RPS previously incompletely resected, and operated in the the participating center for completion surgery -age more than 18 years at the time of the first treatment pediatric patients can not be included -histological confirmed diagnosis according to the WHO criteria done on biopsy or surgical specimen by dedicated sarcoma pathologist -radiological examinations performed contrast enhanced abdominal CT scan and or MRI prior to surgical resection -signed informed consent form -adequate compliance of the patients to the plan of followup

Exclusion criteria

Exclusion criteria: -Age less than 18 years; -recurrent tumor -benign retroperitoneal tumors; -serious psychiatric disease that precludes informed consent or limits compliance -impossibility to ensure adequate followup.

Design outcomes

Primary

MeasureTime frame
This study is aimed to prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers. Patient outcome will be evaluated in terms of overall survival disease free survival crude cumulative incidence of local recurrence and distant metastasisTimepoint: 3 years

Secondary

MeasureTime frame
- to estimate the efficacy and safety of surgical treatment, including extended surgical approach to primary RPS - to prospectively evaluate the impact of multimodality therapy including radiation therapy and chemotherapy - to identify clinical radiological and pathological characteristics that may influence the oncological outcome or may be used as predictors of LR DM OS. These may be important biomarkers of disease - to utilize collected pathological material for research collaborations. Timepoint: 3 years

Countries

Australia, Canada, India, Italy, Netherlands, United States of America

Contacts

Public ContactMahesh goel

Tata Memorial Hospital

drmaheshgoel@gmail.com9820504492

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026